|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Investigations |
1 Department of Neurosurgery, Nagoya University Graduate School of Medicine
2 Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya
3 Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya
* To whom correspondence should be addressed. E-mail: jyoshida{at}med.nagoya-u.ac.jp.
 |
Abstract |
|---|
Gefitinib-a specific inhibitor of epidermal growth factor receptor (EGFR)-associated tyrosine kinase-has demonstrated efficacy in a subgroup of patients with non-small-cell lung carcinoma (NSCLC) who fail conventional chemotherapy. It is also reported to have an antitumor effect in brain metastases from NSCLC. Additionally, EGFR mutations have shown a strong association with gefitinib sensitivity for NSCLC. Here, we assessed the efficacy of gefitinib in brain metastases from NSCLC and evaluated the association of this efficacy with EGFR mutations. We retrospectively reviewed eight cases in which patients were suffering from brain metastases before the initiation of gefitinib treatment. Brain tumor response could be evaluated by MRI in these patients; EGFR gene analyses were also available. We evaluated whether objective tumor response was observed after gefitinib treatment and assessed the efficacy of gefitinib as effective, noneffective, or not assessable in consideration of the influence of previous radiotherapy. Of the eight patients, the efficacy of gefitinib was assessed as effective in three and as noneffective in three. All three patients demonstrating effective efficacy had EGFR mutations in the tyrosine kinase domain (deletion mutation in two patients and point mutation in one patients), whereas none of the three patients demonstrating noneffective efficacy had EGFR mutations. Gefitinib appears to be effective in treating brain metastases in a subgroup of patients. Our data suggested a possible association between the efficacy of gefitinib in the treatment of brain metastases and EGFR mutations.
Key Words: brain metastases, EGFR, gefitinib, mutation
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  E. A. Maher, J. Mietz, C. L. Arteaga, R. A. DePinho, and S. Mohla Brain Metastasis: Opportunities in Basic and Translational Research Cancer Res., August 1, 2009; 69(15): 6015 - 6020. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Gow, Y.-L. Chang, Y.-C. Hsu, M.-F. Tsai, C.-T. Wu, C.-J. Yu, C.-H. Yang, Y.-C. Lee, P.-C. Yang, and J.-Y. Shih Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer Ann. Onc., April 1, 2009; 20(4): 696 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Gow, C.-R. Chien, Y.-L. Chang, Y.-H. Chiu, S.-H. Kuo, J.-Y. Shih, Y.-C. Chang, C.-J. Yu, C.-H. Yang, and P.-C. Yang Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response Clin. Cancer Res., January 1, 2008; 14(1): 162 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Eichler and J. S. Loeffler Multidisciplinary Management of Brain Metastases Oncologist, July 1, 2007; 12(7): 884 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Broniscer, J. C. Panetta, M. O'Shaughnessy, C. Fraga, F. Bai, M. J. Krasin, A. Gajjar, and C. F. Stewart Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 Clin. Cancer Res., March 1, 2007; 13(5): 1511 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
